Using GWAS in a case-control design, 7 we recently identified rs3918226 as a new hypertension susceptibility Abstract-A case-control study revealed association between hypertension and rs3918226 in the endothelial nitric oxide synthase (eNOS) gene promoter (minor/major allele, T/C allele). We aimed at substantiating these preliminary findings by target sequencing, cell experiments, and a population study. We sequenced the 140-kb genomic area encompassing the eNOS gene. In HeLa and HEK293T cells transfected with the eNOS promoter carrying either the T or the C allele, we quantified transcription by luciferase assay. In 2722 randomly recruited Europeans (53.0% women; mean age 40.1 years), we studied blood pressure change and incidence of hypertension in relation to rs3918226, using multivariable-adjusted models. Sequencing confirmed rs3918226, a binding site of E-twenty six transcription factors, as the single nucleotide polymorphism most closely associated with hypertension. In T compared with C transfected cells, eNOS promoter activity was from 20% to 40% (P<0.01) lower. In the population, systolic/diastolic blood pressure increased over 7.6 years (median) by 9. 
H ypertension is a chronic age-related disease influenced by a large number of genetic and environmental factors, lifestyle, and their interaction. 1 Hypertension affects an estimated 25% to 35% of the world's population and >60% of the elderly. [1] [2] [3] In 2001, hypertension caused 8 million deaths worldwide, representing 14% of global mortality. 4 High blood pressure (BP) is the main driver of ischemic heart disease and stroke 3, 4 and substantially exceeds the contribution of the 2 other main modifiable risk factors, hypercholesterolemia and smoking, to the global burden of noncommunicable disease. 4 Several genome-wide association studies (GWAS) identified a number of single-nucleotide polymorphisms (SNPs), all with a small effect on BP. 5, 6 In view of the impact of BP as a continuous risk factor, small genetic effects might entail substantial effects on morbidity and mortality.
locus. This locus lays in the promoter of the endothelial nitric oxide synthase (eNOS) gene, which encodes the enzyme that produces nitric oxide, a strong vasodilator with a key role in the regulation of systemic vascular resistance. GWAS usually points to genomic regions of interest in relation to a trait, but seldom directly identifies the causal or functional variant. In the present study, we aimed at consolidating the role of eNOS as a hypertension susceptibility gene by fine mapping the DNA sequence tagged by rs3918226, by studying the transcriptional functionality of the rs3918226 alleles in vitro, and by relating the change in BP over time to rs3918226 in a randomly recruited population sample.
Methods Target Sequencing
From the HYPERGENES study, 7 we selected 44 hypertensive patients carrying ≥1 T allele and 48 healthy controls homozygous for the C allele. Analyses of the genetic data confirmed that all patients and controls were of continental Italian descent. We sequenced a 140-kb DNA region of chromosome, 7 which, in addition to eNOS, included KCNH2 mapping upstream and 6 genes mapping downstream: ATG9B, ABCB8, ACCN3, CDK5, SLC4A2, and FASTK. Detailed information on the DNA sequencing methods and an accompanying glossary are available in the online-only Data Supplement. We sequenced indexed and multiplexed samples in a paired-end protocol implemented on an Illumina GAIIX platform (Illumina Inc, San Diego, CA).
Paired-end raw reads were checked for their quality using FastQC, version 0.10.0 (http://www.bioinformatics.babraham.ac.uk/projects/ fastqc) and PrinSeq, version 0.19.4 (http://edwards.sdsu.edu/cgibin/prinseq/prinseq.cgi). Reads were aligned to the human reference genome (hg19; UCSC assembly; February 2009) using BWA. SAMtools, Picard (http://picard.sourceforge.net), and Genome Analysis Toolkit (GATK) were used to handle the reads and for postalignment quality control checks. Multisamples variant call was performed by GATK, and quality filters were applied to variant call. Only variants with high SNP quality score were evaluated and annotated with Annovar software for type and impact on the gene product (http://www.openbioinformatics.org/annovar).
We imputed missing genotypes based on the HYPERGENES results with MiniMac, a low memory, computationally efficient implementation of the MaCH algorithm, 8, 9 using as reference panel the 1000 Genome Database, released in June 2011. We tested imputed SNPs with high quality (mean R 2 , 0.91; SD, ±0.11) for association with hypertension, using logistic regression as implemented in Mach2dat 8, 9 with adjustments applied for sex and the first 10 significant principal components.
Luciferase Reporter Assays
We obtained the pGL2-eNOS promoter-luciferase plasmid, carrying the C allele of rs3918226, from Addgene (plasmid 19297; http:// www.addgene.org) and constructed the T allele by site-directed mutagenesis (see Expanded Methods available in online-only Data Supplement). We transfected HeLa cells in 4 independent experiments and each construct was tested in triplicate. HEK293T cells were transfected in 3 independent experiments and each construct was tested in duplicate. We compared luciferase reporter activities between the C and T alleles by Student t test.
Population Study

Study Participants
Recruitment for the Flemish Study on Environment, Genes, and Health Outcomes (FLEMENGHO) started in 1985. 10, 11 From August 1985 to November 1990, a random sample of the households living in a geographically defined area of Northern Belgium was investigated with the goal to recruit an equal number of participants in each of 6 strata by sex and age (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) (35) (36) (37) (38) (39) (40) (41) (42) (43) (44) (45) (46) (47) (48) (49) (50) (51) (52) (53) (54) (55) (56) (57) (58) (59) , and ≥60 years). All household members aged ≥20 years were invited, provided that the quota of their sex-age group had not yet been satisfied. From June 1996 until January 2004, recruitment of families continued using the former participants (1985) (1986) (1987) (1988) (1989) (1990) as index persons and also including teenagers. The participants were repeatedly followed up. In all study phases, we used the same standardized methods to measure BP and to administer questionnaires. 10, 11 The European Project on Genes in Hypertension (EPOGH) recruited participants from 1999 to 2001. 11, 12 The EPOGH investigators received training at the Studies Coordinating Centre in Leuven, Belgium, and applied the same protocol, questionnaires, and follow-up procedures, as used in FLEMENGHO. Questionnaires were translated from Dutch and English into Czech, Italian, Polish, and Russian and back-translated into Dutch and English to ensure that all questions kept the same meaning in all languages. The last follow-up examination took place from 2005 to 2008 in FLEMENGHO 11 and from 2006 to 2008 in EPOGH. 11 Both studies complied with the Helsinki Declaration for investigation of human subjects. 13 Each local institutional review board approved the study protocol. Participants gave written informed consent.
Measurements
At baseline and follow-up, experienced observers measured each participant's anthropometric characteristics and BP and administered the standardized questionnaire to collect information on medical history, smoking and drinking habits, and use of medications, including BP-lowering drugs, contraceptive pill intake, and hormonal replacement therapy. At each contact, BP was the average of 5 consecutive auscultatory readings in the sitting position (see Expanded Methods available in online-only Data Supplement). Digit and number preference was checked at 6-month intervals. 12 Hypertension was an untreated BP of ≥140 mm Hg systolic, or 90 mm Hg diastolic, or use of antihypertensive drugs. For adolescents (n=33), we used the thresholds specified by the European Society of Hypertension, which are stratified by sex, age, and height percentiles.
14 Body mass index was weight in kilograms divided by the square of height in meters.
Datasets for Analysis
From 3785 subjects who initially agreed to participate in FLEMENGHO (n=2593) and EPOGH (n=1192), 53 participants were excluded because the baseline BP measurements were missing, leaving 3732 subjects with a full set of required baseline measurements. Of these, 2981 subjects participated in ≥1 follow-up examination. We additionally excluded 259 participants from analysis because the BP measurements were missing (n=32) or their DNA was of bad quality (n=227). Thus, the blood pressure cohort used to study change in BP included 2722 participants (Figure 1 ). Changes in BP during followup were calculated as the last minus the baseline BP. The hypertension cohort used to study the incidence of hypertension encompassed 2013 participants, who were normotensive at baseline (Figure 1 ). We censored subjects from further analysis after occurrence of the first diagnosis of hypertension.
Statistical Analysis
For database management and statistical analysis, we used SAS software, version 9.3 (SAS Institute Inc, Cary, NC). Between-group comparisons of means, medians, proportions, and Kaplan-Meier survival functions relied on the standard normal z test or ANOVA, Kruskal-Wallis ANOVA or Fisher exact test, and the log-rank test, respectively. We applied McNemar test to evaluate changes over time in categorical variables. We computed 95% confidence intervals (CIs) of rates as R±1.96×√(R/T), where R and T are the rate and the denominator used to calculate the rate.
We studied the association between change in BP and the rs39188226 genotypes, using mixed models with indicator variables (0,1). Multivariable-adjusted models with BP changes as
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November 2013 dependent variables accounted for cohort, sex, age, baseline BP, follow-up duration, baseline and follow-up body mass index, intake of female sex hormones or nonsteroidal antiinflammatory drugs at baseline and follow-up, and 3 indicator variables coding for antihypertensive drug intake (starting or stopping treatment between baseline and follow-up and remaining on treatment). A sensitivity analysis additionally accounted for family clusters modeled as a random effect.
To study the incidence of hypertension, we applied Cox regression adjusted for the same covariables as in the continuous analyses. We checked the proportional hazards assumption by the Kolmogorov supremum test. To account for family clusters, we used the PROC SURVIVAL procedure of the SUDAAN 10.01 software (Research Triangle Institute, NC). We computed the positive predictive value of TT homozygosity as (R×D)/([G/100]×[R-1]+1), where R is the multivariable-adjusted hazard ratio, D is the incidence of hypertension in the whole population (34.5%), and G is the prevalence of TT homozygosity (1.09%). 15 The attributable risk is given by ([R 
Results
Target Sequencing
In 44 hypertensive patients and 48 healthy controls, we captured 91% (SD, 6) of the targeted genomic region with a 63-fold amplification above the genomic background. In each sample, the region of interest was covered on average 20 times with mapping and base quality scores of ≥20 and 17, respectively.
We identified 338 variants, of which 15 were nonsynonymous; 23 synonymous; 23 and 8 in the 3′ UTR and 5′ UTR, respectively; 198 intronic; and 71 intergenic. Among the 338 variants, 277 were already annotated in dbSNP135 (Table  S1 in the online-only Data Supplement) and 61 were novel variants (Table S2) . We had genotyped 76 of 277 annotated SNPs in the HYPERGENES GWAS, using the Illumina 1M array. 7 The genotype concordance rate between the 2 technologies was high (r 2 =≈0.988). Of the 61 novel SNPs, 55 heterozygous variants were rare, only present in a single subject. Table S3 lists the 6 other novel variants. Of these, 3 were intronic in KCNH2 (1 homozygous in 1 subject and 2 other heterozygous in 2 and 4 individuals). One variant was intergenic, mapping ≈3 kb from KCNH2 and 9.5 kb from eNOS (3 heterozygotes). One was intronic in eNOS (2 heterozygotes). One was intronic in ABCB8 (9 heterozygotes and 1 homozygote).
The haplotype analysis appears in page S5 and Figure S1 . Five novel variants were located in a region of linkage disequilibrium upstream of rs3918226. Their annotation did not suggest any functional role (Table S3) . We, therefore, did not consider them in further analyses. Variants imputed in the entire HYPERGENES study population with a probability value of ≤10 -3 appear in Table S4 . rs3918226 remained the SNP most closely associated with hypertension.
Luciferase Reporter Assays
SNP rs3918226 is located in the promoter region of eNOS. Compared with the C allele, the risk-carrying T allele was associated with lower transcriptional activity of the eNOS gene ranging from ≈20% (P<0.0001) when tested in HeLa cells (Figure 2A ) to ≈40% (P<0.01) in HEK293T cells ( Figure 2B ).
Population Study
Characteristics of the Participants
The Table S6 ).
Cross-sectional Analyses of the Blood Pressure Cohort
At baseline (Table) , systolic BP was similar across the rs3918226 genotypes (P=0.42), but TT homozygotes had higher (P=0.030) diastolic BP than C allele carriers. At follow-up (Table) , systolic (P=0.012) and diastolic (P=0.0002) BPs were higher in TT homozygotes than in C allele carriers. The differences in baseline and follow-up systolic and diastolic BPs between the CT and CC genotypes were not statistically significant (P≥0.23; Table) . With adjustments applied for cohort, sex, age, body mass index, and antihypertensive drug intake, baseline (P=0.035) and follow-up (P=0.0007) diastolic BPs and follow-up systolic BP (P=0.038), but not baseline systolic BP (P=0.48), remained higher in TT homozygotes than in C allele carriers. 
Blood Pressure Cohort
Discussion
The key finding of the present study was that rs3918226 in the eNOS promoter tags a hypertension susceptibility locus, TT homozygosity being associated with lesser transcription of the gene product and a 2-fold higher risk of hypertension. Our current findings confirm the previously reported HYPERGENES case-control study. 7 The discovery phase of this project 7 involved 1865 hypertensive patients and 1750 controls, who were genotyped with a Illumina 1M array. The validation study included 1385 cases and 1246 controls, who were genotyped with a 14-K Illumina Infinium custom array. HYPERGENES showed that rs3918226 in the eNOS gene promoter (-665 C>T) tags a hypertension susceptibility locus. 7 The odds ratio associated with the T allele was 1.54 (CI, 1.37-1.73; P=2.58×10 -13 ). In a meta-analysis, using both in silico and de novo genotyping data in 21 714 subjects, the odds ratio was 1.34 (CI, 1.25-1.44; P=1.03×10 -14 ) . 7 In the current study, using BP as a continuous phenotype in a randomly recruited European population sample followed up for 7.6 years (median), systolic and diastolic BPs increased 5.9 and 4.8 mm Hg more in TT homozygotes than in C allele carriers.
Fine mapping the eNOS genomic region in hypertensive patients and healthy controls and imputing approaches in the whole HYPERGENES cohort using 1000 Genome Database released in 2011 as reference further validated rs3918226 as the SNP most closely associated with hypertension. Of 61 novel variants discovered in the genomic area of interest, 55 were singletons with very low minor allele frequency (<0.5%), and 5 were located in a region of linkage disequilibrium and were not functional. The remaining newly discovered variant in the ABCB8 gene located downstream of rs3918226 and was not genotyped in the HYPERGENES sample, because it could not have been tagged by rs3918226 in view of the high recombination rate in this genomic region. In our initial report, 7 we tested whether rs3918226 falls into a regulatory binding site. Using the PATCH algorithm of the TRANSFAC database 16 and the TFSEARCH software 17 (score 87. 3 7 ), we characterized a putative binding site for transcription factors of the ETS (E-twenty six) family only 1 nucleotide away from rs3918226. The members of the ETS family, ETS-1 and ELF-1, are present in endothelial cells and are essential for the activation of the eNOS promoter. 18 We ). Moreover, methylation and acetylation histone marks (H3K4ME1 and H3K27Ac) provide signals above the 98th percentile in the same region.
In our current study, we consolidated our previous results 7 in transfected HeLa and HEK293T cells showing that the T allele, which is the risk factor for hypertension, is associated with a significant reduction of eNOS transcription compared with the C allele. We hypothesize that this can impair endothelial NO production in vivo. Luizon et al 19 reported that the rs3918226 polymorphism does not affect plasma nitrite levels in 181 healthy self-reported blacks. However, Luizon et al's results are difficult to interpret, because rs3918226, according to HapMap data, is not polymorphic in blacks. We, therefore, presume a substantial admixture with whites in this black study population. The T allele frequency was only 0.04. 19 Thus, the low frequency of the risk-conferring T allele and the small sample size probably render a correct estimation of T allele effect on plasma nitrite levels impossible. 20 In mammals, NO can be generated by 3 different isoforms of the enzyme NO synthase, referred to as neuronal nNOS (NOS1), inducible iNOS (NOS2) produced by macrophages, and endothelial eNOS (NOS3). 21 The human eNOS gene spans 21 kb with 26 exons on chromosome 7q35-q36. Blockade of NO synthesis with inhibitory l-arginine analogues leads to peripheral vasoconstriction and a rise in BP. [22] [23] [24] Genetically engineered mice with disrupted eNOS are hypertensive and have no endothelium-derived relaxant activity. 25 The physiologically most important determinants for the continuous generation of NO and thus the regulation of local blood flow are fluid shear stress and pulsatile stretch. 26 NO dilates all types of blood vessels by stimulating soluble guanyl cyclase and increasing the cGMP concentration in smooth muscle cells. 22 eNOS is not only a physiological vasodilator but also conveys vascular protection in several ways. 21, 22 NO released toward the vascular lumen is a potent inhibitor of platelet aggregation and adhesion to the vascular wall and prevents the release of platelet-derived growth factors that stimulate smooth muscle proliferation. NO decreases the expression of chemoattractant protein MCP-1 (Monocyte chemoattractant protein) and of a number of surface adhesion molecules and inhibits leukocyte adhesion to vascular endothelium and leukocyte migration into the vascular wall. This offers protection against the early phases of atherosclerosis. 22 The decreased endothelial permeability, the reduced influx of lipoproteins into the vascular wall, and the inhibition of low-density lipoprotein oxidation contribute to the antiatherosclerotic properties of eNOS-derived NO. Finally, NO inhibits DNA synthesis and proliferation of vascular smooth muscle cells as well as smooth muscle cell migration, thereby protecting against the later stages of atherogenesis. 22 Given the central role of eNOS in cardiovascular regulation, several previous studies addressed the association between hypertension or cardiovascular disease and genetic variation in eNOS. Niu Moreover, the T allele of T-786C polymorphism is a predisposing factor to coronary spasm and reduces the eNOS promoter activity. 28 The candidate gene and GWAS studies published so far on hypertension 6 identified 47 distinct genetic variants robustly associated with BP, but collectively these variants explained only a few percent of the heritability of BP. HYPERGENES was the first GWAS to identify rs3918226 (C-685T) as a hypertension susceptibility locus. 7 An international consortium applied a gene-centric assay in an independent discovery sample of 25 118 individuals that combined hypertensive case-control and general population samples and followed up 10 suggestive SNPs in a further 59 349 individuals. 6 An analysis of combined discovery and follow-up data identified rs3918226 (T/C: 0.08/0.92) as being significantly (2.2×10 -9 ) associated with diastolic BP. The effect size per -690T allele was +0.78 mm Hg (SE, 0.21; P=9.5×10 -5 ). 6 The recent GWAS of systolic and diastolic BP performed by the International Consortium for Genome-Wide Association Studies (ICBP) used a multi-stage design in 200 000 individuals of European descent. 29 Overall, the eNOS region was poorly covered in this study. Genotyping had been performed in most of the cohorts with arrays older that the Illumina 1M, which do not include rs3918226. Moreover, imputation was done using the HapMap panel as reference that does not include rs3918226. In the ICBP data set, 29 a SNP mapping 779 bp from rs3918226, rs1800783 (position 150689397), shows a high D′ (1.000) but a low R-sq (0.141) with rs3918226. Because of the low R-sq, allele frequencies are different, and rs1800783 cannot be considered a proxy of rs3918226. In GenHAT, 30 the hazard ratio for the primary end point, fatal coronary heart disease, and nonfatal myocardial infarction in T allele versus CC genotype carriers was 1.12 (CI, 1.00-1.26; P=0.048). Conen et al 31 analyzed 3 SNPs in the eNOS gene (rs3918226, rs1800779, and rs1799983) in 18 436 white women enrolled in the Women's Health Study. The participants were all health professionals and normotensive at baseline. BP was self-reported. Over 9.8 years, 29.6% of the women developed hypertension. The hazard ratios for the eNOS polymorphisms were 1.01 (CI, 0.97-1.06), 1.06 (CI, 0.99-1.14), and 1.05 (CI, 1.01-1.09), respectively. 31 Progression of BP across 3 increasing categories was not associated with the eNOS polymorphisms, but follow-up for this soft end point was only 4 years. Seidlerová et al 32 reported a pilot study examining the association between arterial properties and the rs3918226 polymorphism in 101 untreated volunteers. Among 31 smokers, carriers of the mutated T allele (n=8) had a marginally higher aortic pulse wave velocity (10.0 versus 8.7 m/s; P=0.051) and a higher aortic augmentation index (172 versus 153%; P=0.024). Seidlerová et al 32 hypothesized that pending confirmation in a larger study genetic modulation of intermediate arterial phenotypes might lead to higher BP.
Taking into account our current findings and the literature, the C to T substitution at position -690 in the eNOS promoter strongly complies with the Bradford Hill criteria 33 as a cause of hypertension. The association is strong, 6, 7, 27 consistent across studies, 6, 7, 27 and specific for hypertension-or hypertension-related complications. 6, 7, 27, 30 The current study established temporality and provided a possible mechanism adding to the plausibility. Some studies, but not ours, suggested a dose effect based on the number of T alleles.
6,27
Perspectives
We demonstrated that TT homozygosity at the rs3918226 locus in the eNOS gene promoter enhances the age-related increase in BP and increases the risk of hypertension, probably by reducing the transcriptional activity of the eNOS gene. The implications of our current findings span both the prevention and treatment of hypertension and its associated cardiovascular complications. The prevalence of TT homozygosity is low, explaining why the population-attributable risk for hypertension is only 1.1%. However, the attributable risk in TT homozygotes is 51.0%. Combined with other genetic markers, the rs3918226 polymorphism might, therefore, contribute to the stratification of cardiovascular risk. Our findings also support pharmacological interference with the NO signaling pathway. In GenHAT, 30 amlodipine, compared with lisinopril, was more effective in the prevention of stroke in minor allele carriers (hazard ratios CT+TT versus CC: 0.49 versus 0.85; P=0.04). Overall, amlodipine reduced systolic BP 1.2 mm Hg more than lisinopril. 34 Stroke is the complication of hypertension that is most closely linked to the BP level. 1 Moreover, amlodipine enhances endothelial NO availability via stimulation of NO formation 35 and by prolonging the NO half-life through antioxidative properties. 35, 36 Recently developed compounds act downstream in the NO signaling pathway by inhibition of cGMP-specific phosphodiesterase type 5 37 or by stimulation (haem-dependent) or activation (NO-and haem-independent) of soluble guanylate cyclase activity. 38 Further clinical research should establish whether eNOS might be a target for preventive or therapeutic intervention. 
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HYPERTENSION Expanded Methods and Data Supplement
This Data Supplement has been provided by the authors to give readers additional information about their work. Cell lines and cultures-We grew HeLa and HEK293TT cells in Dulbecco's modified Eagle's medium (Sigma), 10% fetal bovine serum, 100 units/ml penicillin, 100 μg/ml streptomycin, 2 mM-glutamine.
Transfections and luciferase assay-We used lipofection to transiently co-transfect 5 x 10 4 HeLa cells with the pGL2-eNOSpromoter-luciferase plasmid, carrying the C or T allele of rs3918226, and the pRL-CMV plasmid (Promega) to normalize transfection efficiency. As negative control, we co-transfected Hela cells with the empty pGL2 vector and the pRL-CMV plasmid. We performed the transfections, using FuGENE (Promega) according to the manufacturer's instructions. We measured the Firefly and Renilla luciferase activity 48 hours after transfection by the Dual-Luciferase Reporter Assay System (Promega). We did all transfections in triplicate and tested each construct in 4 independent experiments. The same constructs were used to transfect HEK293T cells, using FuGENE (Promega). Each condition was tested 6 times in a 96-well plate format and luminescence was measured 24 hours after transfection. Three independent replicates were performed.
Population Study
Blood pressure measurement-After the participants had rested for 5 minutes in the sitting position, the study nurses obtained 5 consecutive blood pressure readings (phase V diastolic pressure) to the nearest 2 mm Hg, using mercury sphygmomanometers. Standard cuffs had a 12 × 24 cm inflatable portion, but if upper arm girth exceeded 31 cm, larger cuffs with 15 × 35 cm bladders were used. For analysis, the 5 blood pressure readings obtained at baseline or at follow-up were averaged.
At each field center, quality assurance sessions were organized at 6-monthly intervals to reinforce the theoretical concepts of auscultatory blood pressure and to rehearse the procedure. 6 At each session, the observers had to pass a test requiring them to read blood pressures from a videotape featuring a falling mercury column with simultaneous Korotkoff sounds (Measuring Blood Pressure, British Medical Association, London, 1990). For each session, a specific standard was computed by averaging the film readings of experienced senior clinical researchers. All readings from each observer had to be within 5 mm Hg of the standard. Observers failing to pass the test did not participate in blood pressure measurement until re-tested successfully at a later session. We checked digit and number preference at 6-month intervals. 6 
Results
Sequencing vs. GWAS
In 44 hypertensive patients and 48 healthy controls enrolled in HYPERGENES, 7 we identified 338 putatively high-confidence variants: 61 novel (web table 1) and 277 already annotated in the dbSNP, version 135 database (Table S2 ). The high proportion of variants in dbSNP (82%) and the transition/transversion rate (Ti/Tv = 2.19) suggest a high truly positive rate for these data.
Of 277 annotated SNPs, 76 were common in the HYPERGENES GWAS study 7 that was done with the Illumina 1M array. This allowed evaluating genotype concordance between the two technologies. The concordance rate was high (r 2 ~0.988). For these 76 SNPs, we compared allele frequencies between cases and controls using the sequencing or GWAS approach. We noticed substantially comparable allele frequencies for all SNPs except for those mapping in the KCNH2 gene, upstream eNOS. This was likely due to an extended linkage disequilibrium (LD) block upstream rs3918226 and to the selection of participants for sequencing based on the presence or absence of the T risk allele at rs3918226.
Linkage Disequilibrium and Haplotype Analysis
In the HYPERGENES sample (n=3615), 7 we performed a pairwise linkage disequilibrium (LD) and haplotype analysis, using Haploview (http://www.broadinstitute.org/scientificcommunity/science/programs/medical-and-population-genetics/haploview/haploview). We identified 2 large LD blocks upstream rs3918226, spanning from rs758887 to rs3918226 ( Figure S1 ). The pairwise D' between rs3918226 and the SNPs mapping in the same LD block ( Figure S1 ) was high (>0.79), whereas r 2 was low (<0.29). In spite of the low r 2 , all participants carrying the T risk allele at rs3918226 had a single haplotype that extended from rs3918226 to rs2968857. This haplotype including the G allele at rs2968857and the T risk al-lele at rs3918226 covered approximately 28 kb upstream of rs3918226 and was more frequent in cases than controls (0.10 vs. 0.07, P=3.02 E10 -5 ). Nevertheless, the association of hypertension with this haplotype was not more informative than with the rs3918226 single SNP (P=1.64 E10 -6 ). We did therefore not test the novel variants mapping upstream of rs3918226 in the entire HYPERGENES sample. 7 The only novel SNP mapping downstream of eNOS in ABCB8 gene was not genotyped in HYPERGENES, 7 because it could not be tagged by rs3918226 due to the high recombination rate in this genomic area. Five novel variants were located in a region of linkage disequilibrium upstream rs3918226. Their annotation did not suggest any functional role. For this reason, we did not consider them in further analyses.
Population Study
Characteristics of participants by sex-Women compared to men (p≤0.0001) had lower sys- 
Glossary
SNP
Single nucleotide polymorphism -a site of the genome that differs by a single nucleotide (base pair) between individual people
ALLELE
A number of alternative forms of the same gene or same genetic locus.
LD
Linkage disequilibrium -the non-random association of 2 alleles at 2 different loci on the same chromosome and therefore a measure of co-segregation of alleles in a population HAPLOTYPE A combination of alleles (DNA sequences) at adjacent locations (loci) on the chromosome that are transmitted together
DNA SEQUENCING
Measurement of the precise order of the nucleotides (the 4 bases, adenine, guanine, cytosine, and thymine) in a strand of DNA
INDEXING
Tagging different DNA samples with a unique identifier, a short nucleotide sequence.
MULTIPLEXING
When DNA samples are indexed, they can be pooled in a single sample, and sequenced together. During data analysis samples can be easily identified.
TAGGING SNP
A SNP that is in strong linkage disequilibrium with multiple other SNPs, so that it can serve as proxy for these SNPs. 
Figure S1. Haplotype Blocks Upstream of rs3918226
Haplotype 1 spans from rs758887 to rs6947240; haplotype 2 spans from rs2968857 to rs3948226. Haplotype 2 carrying the G allele at rs2968857 and the T risk allele at rs3918226 was more frequent in cases (0.10) than controls (0.07).
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